Doorgaan naar hoofdnavigatie
Doorgaan naar zoeken
Ga verder naar hoofdinhoud
Sorteer per
Medicine and Dentistry
Acute Lymphoblastic Leukemia
58%
Acute Myelogenous Leukemia
20%
Acute Myeloid Leukemia
100%
Adolescence
23%
Cancer
12%
Cancer Therapy
18%
Cancer-Related Fatigue
10%
Chemotherapy
55%
Childhood Cancer
93%
Childhood Leukemia
9%
Clinical Trial
13%
Cohort Analysis
11%
Cumulative Incidence
9%
Cytarabine
13%
Diseases
29%
Doxorubicin
9%
Drug Megadose
8%
Drug Resistance
8%
Event Free Survival
27%
Ganglioglioma
12%
Ganglioneuroblastoma
13%
Health Care Personnel
9%
High Risk Population
13%
Infusion
8%
Injection
9%
Leukemia
18%
Low and Middle Income Countries
12%
Malignant Neoplasm
38%
Minimal Residual Disease
14%
Neoplasm
9%
Oncology
16%
Overall Survival
33%
Patient Referral
9%
Pediatric Acute Myeloid Leukemia
67%
Pediatrics
58%
Pediatrics Patient
17%
Pontine Glioma
42%
Prognostic Factor
8%
Quality of Life
11%
Radiation Therapy
13%
Randomized Controlled Trial
9%
Reproductive Medicine
8%
Retrospective Study
11%
Supportive Care
15%
Survival Rate
16%
Treatment Outcome
22%
Treatment Response
8%
Tumor
16%
Vincristine
13%
Wilms' Tumor
9%
Keyphrases
Acute Lymphoblastic Leukemia
45%
Acute Lymphoblastic Leukemia Cells
11%
Acute Myeloid Leukemia
95%
Cellular Drugs
16%
Chemotherapy
16%
Childhood Acute Lymphoblastic Leukemia
61%
Childhood Cancer
24%
Childhood Cancer Patients
14%
Childhood Cancer Treatment
13%
Childhood Leukemia
12%
Children with Cancer
30%
Cytarabine
17%
Daunorubicin
11%
Deoxycytidine Kinase
12%
Diffuse Intrinsic Pontine Glioma
52%
Drug Resistance
23%
Dutch
34%
Event-free Survival
17%
Health-related Quality of Life
16%
Healthcare Providers
11%
High Risk
12%
Kenya
17%
L-asparaginase
15%
Late Effects
14%
Leukemia
16%
Leukemia Patients
16%
Low-middle Income Countries
10%
Methotrexate
16%
Netherlands
13%
Newly Diagnosed
15%
Oncology
13%
Overall Survival
23%
Pediatric
33%
Pediatric Acute Lymphoblastic Leukemia
20%
Pediatric Cancer Patients
11%
Pediatric Leukemia
71%
Pediatric Oncology
16%
Pediatric Patients
19%
Prednisolone
15%
Prognostic Significance
13%
Quality of Life
16%
Radiotherapy
13%
Randomized Controlled Trial
16%
Relapsed Acute Myeloid Leukemia
15%
Supportive Care
12%
Survivors
11%
Treatment Outcome
11%
Tumor
12%
Vincristine-induced Peripheral Neuropathy
16%
Women Survivors
10%
